학술논문
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
Document Type
Article
Author
Bosch, Floris T.M.; Mulder, Frits I.; Huisman, Menno V.; Zwicker, Jeffrey I.; Di Nisio, Marcello; Carrier, Marc; Segers, Annelise; Verhamme, Peter; Middeldorp, Saskia; Weitz, Jeffrey I.; Grosso, Michael A.; Duggal, Anil; Büller, Harry R.; Wang, Tzu‐Fei; Garcia, David; Kamphuisen, Pieter Willem; Raskob, Gary E.; van Es, Nick
Source
Journal of Thrombosis and Haemostasis; December 2021, Vol. 19 Issue: 12 p3008-3017, 10p
Subject
Language
ISSN
15387933; 15387836
Abstract
In the Hokusai VTE Cancer study, the risk of major bleeding was 2.9% higher in the edoxaban group compared with the dalteparin group, mainly due to more gastrointestinal bleedings in patients with gastrointestinal cancer. The identification of risk factors for gastrointestinal bleeding may help to guide the use of DOACs in these patients.